Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $1 million versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.